Insider · CIK 0001628880

Pagan Douglas W.

Reports to the SEC for 4 companies · WALTHAM, MA

sec.gov

Transactions

Companies

Filings

CIK

0001628880

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-04-16	KLRAKailera Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+100K sh	—	—	100,000
2026-04-16	KLRAKailera Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+100K sh	—	—	100,000
2021-12-28	Dicerna Pharmaceuticals IncU Disposition from Tender	Chief Financial Officer	UDisposition from Tender	−7,775 sh	$38.25	−$297K	0
2021-12-28	Dicerna Pharmaceuticals IncRestricted Stock UnitsD Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−20.5K sh	—	—	0
2021-12-28	Dicerna Pharmaceuticals IncRestricted Stock UnitsD Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−6,150 sh	—	—	0
2021-12-28	Dicerna Pharmaceuticals IncEmployee Stock Option (Right to Buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−95.7K sh	—	—	0
2021-12-28	Dicerna Pharmaceuticals IncEmployee Stock Option (Right to Buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−36.9K sh	—	—	0
2021-12-15	Dicerna Pharmaceuticals IncM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+2,050 sh	—	—	8,377
2021-12-15	Dicerna Pharmaceuticals IncF Tax Payment	Chief Financial Officer	FTax Payment	−602 sh	$38.05	−$22.9K	7,775
2021-12-15	Dicerna Pharmaceuticals IncRestricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−2,050 sh	—	—	6,150
2021-06-15	Dicerna Pharmaceuticals IncM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+6,825 sh	—	—	7,764
2021-06-15	Dicerna Pharmaceuticals IncF Tax Payment	Chief Financial Officer	FTax Payment	−2,004 sh	$35.74	−$71.6K	5,760
2021-06-15	Dicerna Pharmaceuticals IncRestricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−6,825 sh	—	—	20,475
2021-01-12	Dicerna Pharmaceuticals IncRestricted Stock UnitsA Award	Chief Financial Officer	AAward	+8,200 sh	—	—	8,200
2021-01-12	Dicerna Pharmaceuticals IncEmployee Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+36.9K sh	—	—	36,900
2020-06-01	Dicerna Pharmaceuticals IncRestricted Stock UnitsA Award	Chief Financial Officer	AAward	+27.3K sh	—	—	27,300
2020-06-01	Dicerna Pharmaceuticals IncEmployee Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+95.7K sh	—	—	95,650
2019-12-31	TCRTAlaunos Therapeutics, Inc.A Award	Director	AAward	+15.9K sh	—	—	55,997
2019-12-31	TCRTAlaunos Therapeutics, Inc.F Tax Payment	Director	FTax Payment	−20.1K sh	$4.72	−$94.7K	35,943
2019-12-31	TCRTAlaunos Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+25.3K sh	—	—	25,281
2019-04-05	Paratek Pharmaceuticals, Inc.D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−19.5K sh	—	—	151,557
2019-04-05	Paratek Pharmaceuticals, Inc.D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−37K sh	—	—	114,557
2019-04-05	Paratek Pharmaceuticals, Inc.D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−27.5K sh	—	—	87,057
2019-04-05	Paratek Pharmaceuticals, Inc.D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−16.3K sh	—	—	70,807
2019-04-05	Paratek Pharmaceuticals, Inc.A Award	Chief Financial Officer	AAward	+30K sh	—	—	100,807
2019-02-26	Paratek Pharmaceuticals, Inc.A Award	Chief Financial Officer	AAward	+37K sh	—	—	171,057
2019-02-05	Paratek Pharmaceuticals, Inc.S Sale	Chief Financial Officer	SSale	−2,495 sh	$6.77	−$16.9K	134,057
2019-02-01	Paratek Pharmaceuticals, Inc.A Award	Chief Financial Officer	AAward	+16.3K sh	—	—	136,552
2018-12-31	TCRTAlaunos Therapeutics, Inc.A Award	Director	AAward	+40.1K sh	—	—	40,107
2018-12-31	TCRTAlaunos Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+63.4K sh	—	—	63,350
2018-12-12	Paratek Pharmaceuticals, Inc.S Sale	Chief Financial Officer	SSale	−2,918 sh	$6.76	−$19.7K	120,302
2018-10-15	Paratek Pharmaceuticals, Inc.S Sale	Chief Financial Officer	SSale	−2,784 sh	$8.96	−$24.9K	123,220
2018-10-12	Paratek Pharmaceuticals, Inc.A Award	Chief Financial Officer	AAward	+6,500 sh	—	—	126,004
2018-10-03	Paratek Pharmaceuticals, Inc.S Sale	Chief Financial Officer	SSale	−7,579 sh	$9.82	−$74.4K	119,504
2018-10-02	Paratek Pharmaceuticals, Inc.A Award	Chief Financial Officer	AAward	+22.5K sh	—	—	99,583
2018-10-02	Paratek Pharmaceuticals, Inc.A Award	Chief Financial Officer	AAward	+27.5K sh	—	—	127,083
2018-09-18	TCRTAlaunos Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+50K sh	—	—	50,000
2018-04-09	Paratek Pharmaceuticals, Inc.S Sale	Chief Financial Officer	SSale	−5,237 sh	$12.70	−$66.5K	77,083
2018-04-03	Paratek Pharmaceuticals, Inc.A Award	Chief Financial Officer	AAward	+13.5K sh	—	—	82,320
2018-02-14	Paratek Pharmaceuticals, Inc.A Award	Chief Financial Officer	AAward	+29.3K sh	—	—	68,820
2018-02-05	Paratek Pharmaceuticals, Inc.S Sale	Chief Financial Officer	SSale	−16.3K sh	$14.22	−$232K	39,570
2017-07-05	Paratek Pharmaceuticals, Inc.S Sale	Chief Financial Officer	SSale	−4,139 sh	$23.58	−$97.6K	55,861
2017-07-03	Paratek Pharmaceuticals, Inc.A Award	Chief Financial Officer	AAward	+9,000 sh	—	—	60,000
2017-06-19	Paratek Pharmaceuticals, Inc.S Sale	Chief Financial Officer	SSale	−4,595 sh	$25.00	−$115K	51,000
2017-02-06	Paratek Pharmaceuticals, Inc.S Sale	Chief Financial Officer	SSale	−17 sh	$15.20	−$258.4	58,983
2017-02-06	Paratek Pharmaceuticals, Inc.S Sale	Chief Financial Officer	SSale	−732 sh	$15.15	−$11.1K	58,251
2017-02-06	Paratek Pharmaceuticals, Inc.S Sale	Chief Financial Officer	SSale	−1,428 sh	$15.10	−$21.6K	56,823
2017-02-06	Paratek Pharmaceuticals, Inc.S Sale	Chief Financial Officer	SSale	−17 sh	$15.07	−$256.275	56,806
2017-02-06	Paratek Pharmaceuticals, Inc.S Sale	Chief Financial Officer	SSale	−1,186 sh	$15.05	−$17.8K	55,620
2017-02-06	Paratek Pharmaceuticals, Inc.S Sale	Chief Financial Officer	SSale	−25 sh	$15.09	−$377.25	55,595

Recent filings

Accepted (ET)
Apr 204
Pagan Douglas W.0001193125-26-164210
SEC(opens sec.gov)
Dec 294
Pagan Douglas W.0001399529-21-000203
SEC(opens sec.gov)
Dec 174
Pagan Douglas W.0001399529-21-000178
SEC(opens sec.gov)
Jun 174
Pagan Douglas W.0001399529-21-000121
SEC(opens sec.gov)
Jan 124
Pagan Douglas W.0001399529-21-000011
SEC(opens sec.gov)
Jun 24
Pagan Douglas W.0000899243-20-014950
SEC(opens sec.gov)
Jan 34
Pagan Douglas W.0001209191-20-001183
SEC(opens sec.gov)

Companies

Address

C/O KAILERA THERAPEUTICS, INC. 180 THIRD AVENUE, 4TH FLOOR

WALTHAM, MA, 02451